Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypercholesterolemia: full-pipeline trial registry
5 of 63 indexed Hypercholesterolemia trials are currently recruiting.
Corpus placement: #222 of 28,707 conditions by registered trial count.
63 US clinical trials · 5 currently recruiting · #222 of 28,707 conditions by registered trial count
Hypercholesterolemia: 63 US clinical trials tracked, 5 recruiting.
Hypercholesterolemia is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis, running 4 of these trials.
Enrollment posture brief
Registry condition hypercholesterolemia
OPEN 5 | RECR 8% | LATE 26 | EARLY 18 | RANK #222 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Sinusitis (8% recruiting · 13 trials)
Hypercholesterolemia lists 5 open slots (8% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypercholesterolemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypercholesterolemia is recruiting below its size-band peers.
5 of 63 indexed trials (7.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hypercholesterolemia trials is spread across many organizations.
Novartis accounts for 4 of 63 trials (6.3%). 41 distinct sponsors appear on at least one study for this condition label.
-
Typical Hypercholesterolemia enrolment sits around 143 participants.
Median target enrolment is 143 among the 63 trials that report a genuine target (sentinel values excluded). 24 of those (38.1%) plan for fewer than 100 participants.
-
Hypercholesterolemia research is mostly interventional.
56 interventional and 7 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
63 total, page 1 of 2
Causes and Natural History of Dyslipidemias
National Heart, Lung, and Blood Institute (NHLBI)
NCT00353782
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Tulane University
NCT06065098
Pharmacogenomic Informed Statin Prescribing
VA Office of Research and Development
NCT06568601
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Wake Forest University Health Sciences
NCT06488105
Pharmacokinetics of Butyrate Tablet BKR-017
BioKier
NCT06556745
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Merck Sharp & Dohme
NCT06492291
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
University of Utah
NCT06423365
Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy
Johns Hopkins University
NCT02694094
Evaluating the Efficacy of Pediatric Lipid Screening Alerts
Geisinger Clinic
NCT04118348
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
National Heart, Lung, and Blood Institute (NHLBI)
NCT00000620
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Sanofi
NCT01507831
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Regeneron Pharmaceuticals
NCT02957682
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
AstraZeneca
NCT00525824
Actual Use Trial of Atorvastatin Calcium 10 mg
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT01964326
Study of a Holistic Health Program for United Methodist Clergy
Duke Clergy Health Initiative
NCT01564719
Cholesterol and Pharmacogenetic Study
UCSF Benioff Children's Hospital Oakland
NCT00451828
Open Label Study of Long Term Safety Evaluation of Alirocumab
Sanofi
NCT01954394
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Amgen
NCT01813422
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Regeneron Pharmaceuticals
NCT01926782
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
Novartis
NCT06595069
Potential Risk Factors for Stroke
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001368
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Amgen
NCT02739984
Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia
Takeda
NCT00249912
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
Novartis
NCT00385931
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
Novartis
NCT00171093
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
Novartis Pharmaceuticals
NCT05763875
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
Esperion Therapeutics
NCT01941836
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Sanofi
NCT01644175
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Merck Sharp & Dohme
NCT05952869
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
Merck Sharp & Dohme
NCT06450366
Metabolic Abnormalities in HIV Infected and Uninfected Young Women
University of North Carolina, Chapel Hill
NCT00067587
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
Esperion Therapeutics
NCT03001076
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
National Heart, Lung, and Blood Institute (NHLBI)
NCT01212900
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
Ironwood Pharmaceuticals
NCT00404001
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
Esperion Therapeutics
NCT02178098
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
University of Kansas Medical Center
NCT01660191
A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects
Pfizer
NCT01720537
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
Daiichi Sankyo
NCT00754039
Diets Enriched With Pecans
University of Georgia
NCT04376632
The Effect of BiosLife on Serum Lipids
University of Utah
NCT00457756
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
Catabasis Pharmaceuticals
NCT01912560
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
Mayo Clinic
NCT00217061
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
Novartis
NCT06507852
Study of the Response of Human Small Blood Vessels
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001622
Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00917579
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
Novartis Pharmaceuticals
NCT01979601
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
Regeneron Pharmaceuticals
NCT01161082
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.
Daiichi Sankyo
NCT00753779
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Pfizer
NCT01243151
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
Esperion Therapeutics
NCT03051100
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 10 |
| Phase 3 | 18 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypercholesterolemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypercholesterolemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypercholesterolemia page
63 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Hypercholesterolemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis sponsors the most Hypercholesterolemia trials on record, review their full trial history before evaluating a specific study. See Novartis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypercholesterolemia condition card totals 63 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.